Immunovant stock hits 52-week high at 41.37 USD
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunovant Inc (IMVT)
The Immunovant share price today is 44.37, view NASDAQ IMVT stock exchange data. Track the latest Immunovant share price with real-time updates on IMVT stock performance including market cap, day range, 52-week range and dividend yield. Access IMVT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
44.08
45.12
52 wk Range
14.47
45.42
IMVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
44.0845.12
52 wk Range
14.4745.42
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMVT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
47.88
Upside
+7.90%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Form 8K Immunovant Inc For: 6 August- Investing.com
- Immunovant stock hits 52-week high at 41.37 USD
- Investing.com
Immunovant Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
12 Buy
4 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 47.88
(+7.90% Upside)
Immunovant Inc SWOT Analysis
Pioneering Treatment | Immunovant's novel anti-FcRn therapy shows promise for autoimmune diseases, particularly Graves' disease, with potential for best-in-class efficacy |
Market Potential | Explore the substantial opportunity in Graves' disease, with an estimated 20,000 high-need patients diagnosed annually in the US |
Analyst Optimism | Price targets range from $36 to $58, suggesting significant upside potential despite recent stock decline. Average target stands at $57 |
Strategic Expansion | Delve into Immunovant's ambitious plan to target 10 indications by 2026, diversifying risk and expanding market potential |
Immunovant Inc Earnings Call Summary for Q1/2027
- Roivant posted Q1 2026 EPS of -$0.75, missing analyst estimates of -$0.60 by 25%, with shares down 1.25% to $38.79 in premarket trading.
- Cash position stood at $4B before receiving $950M Moderna settlement; company spent $200M on R&D and repurchased $200M in shares during quarter.
- Dermatomyositis launch team fully deployed ahead of potential FDA approval by September 2026, marking first targeted therapy launch in the disease.
- Management expects 'jam-packed second half' with multiple catalysts: PH-ILD, NIU, and D2T RA data readouts plus FDA meeting scheduled for fall 2026.
- No detailed financial guidance provided; company continues elevated R&D spending across broad pipeline with profitability timeline remaining distant.
Last Updated: 06-08-2026, 07:10 pm
Read Full TranscriptEarnings
Latest Release
06-08-2026
EPS / Forecast
-0.75 / -0.60
Revenue / Forecast
-- / --
Compare IMVT to Peers and Sector
Metrics to compare | IMVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMVTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.0x | −1.7x | −0.3x | |
PEG Ratio | −25.90 | −0.03 | 0.00 | |
Price/Book | 12.5x | 3.8x | 2.6x | |
Price / LTM Sales | - | 9.5x | 3.1x | |
Upside (Analyst Target) | 9.7% | 143.9% | 47.6% | |
Fair Value Upside | Unlock | 5.0% | 5.6% | Unlock |
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren’s disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Immunovant (IMVT) Share Price Today?
The Immunovant share price today is 44.37.
What is the current Immunovant (IMVT) share price and day range?
As of 22-08-2026, the Immunovant share price is 44.37, with a previous close of 44.35. The share price has ranged from 44.08 to 45.12 today, while the 52-week range spans from 14.47 to 45.42.
What Is the Immunovant Market Cap?
As of today, Immunovant market cap is 9.16B.
What Is the Immunovant (IMVT) Share Price Target?
The average 12-month share price target for Immunovant is 47.88, with a high estimate of 66 and a low estimate of 24. 12 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +7.90% Upside potential.
What Is Immunovant's Earnings Per Share (TTM)?
The Immunovant EPS (TTM) is -2.82.
When Is the Next Immunovant Earnings Date?
Immunovant will release its next earnings report on 18-11-2026.
From a Technical Analysis Perspective, Is IMVT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Immunovant Trade On?
Immunovant is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Immunovant?
The stock symbol for Immunovant is "IMVT."
How Many Times Has Immunovant Stock Split?
Immunovant has split 0 times.
How Many Employees Does Immunovant Have?
Immunovant has 315 employees.
What Is the IMVT Premarket Price?
IMVT's last pre-market stock price is 45.02. The pre-market share volume is 2,650.00, and the stock has changed by 0.67, or 1.51%.
What Is the IMVT After Hours Price?
IMVT's last after hours stock price is 43.73, the stock has changed by -0.64, or -1.44%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.